Palisade Bio, Inc.
PALI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357459
In the last 90 days, Palisade Bio, Inc. insiders filed 2 open-market purchases and 2 sales; 124 institutions reported holding it in 13F filings for Q2 2026, worth $362.4M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Palisade Bio, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 10 | 13 | +3 |
| Shares | 235.0K | 296.4K | +61.4K (+26.1%) |
| Value | $387.7K | $200.9K | −$186.8K (−48.2%) |
New holders (4)
Institutions that held Palisade Bio, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HRT Financial LP | 18,264 | $12.0K | 0.00% |
| Virtu Financial LLC | 15,255 | $10.0K | 0.00% |
| Two Sigma Securities, LLC | 14,153 | $9.63K | 0.00% |
| Barclays PLC | 6 | $4 | 0.00% |
Sold out (1)
Institutions that held Palisade Bio, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Cetera Investment Advisers | 70,006 | $115.5K |